Alnylam Pharmaceuticals, Inc. Announces Sales Results for the Fourth Quarter and Full Year 2021
For the year, company reported Preliminary global net product revenues of $475 million, representing annual growth of 55% compared to full year 2020.
Market Closed -
Other stock markets
|
After market 19:00:04 | |||
245.2 USD | +2.09% |
|
246.1 | +0.39% |
1st Jan change | Capi. | |
---|---|---|
+28.09% | 31.01B | |
+23.13% | 46.93B | |
+37.49% | 39.08B | |
-8.73% | 38.48B | |
-12.26% | 26.14B | |
+10.57% | 25.88B | |
+45.05% | 14.15B | |
+32.23% | 12.53B | |
-6.56% | 11.36B | |
-12.56% | 10.65B |